JP2013540771A5 - - Google Patents

Download PDF

Info

Publication number
JP2013540771A5
JP2013540771A5 JP2013533235A JP2013533235A JP2013540771A5 JP 2013540771 A5 JP2013540771 A5 JP 2013540771A5 JP 2013533235 A JP2013533235 A JP 2013533235A JP 2013533235 A JP2013533235 A JP 2013533235A JP 2013540771 A5 JP2013540771 A5 JP 2013540771A5
Authority
JP
Japan
Prior art keywords
insulin
terminal
pharmaceutical composition
terminally modified
modified insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013533235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013540771A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/068019 external-priority patent/WO2012049307A2/en
Publication of JP2013540771A publication Critical patent/JP2013540771A/ja
Publication of JP2013540771A5 publication Critical patent/JP2013540771A5/ja
Withdrawn legal-status Critical Current

Links

JP2013533235A 2010-10-15 2011-10-14 新規n末端修飾インスリン誘導体 Withdrawn JP2013540771A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10187706.6 2010-10-15
EP10187706 2010-10-15
US39409010P 2010-10-18 2010-10-18
US61/394,090 2010-10-18
PCT/EP2011/068019 WO2012049307A2 (en) 2010-10-15 2011-10-14 Novel n-terminally modified insulin derivatives

Publications (2)

Publication Number Publication Date
JP2013540771A JP2013540771A (ja) 2013-11-07
JP2013540771A5 true JP2013540771A5 (enExample) 2014-11-20

Family

ID=43638785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013533235A Withdrawn JP2013540771A (ja) 2010-10-15 2011-10-14 新規n末端修飾インスリン誘導体

Country Status (5)

Country Link
US (1) US20140315797A1 (enExample)
EP (1) EP2627670A2 (enExample)
JP (1) JP2013540771A (enExample)
CN (1) CN103154024A (enExample)
WO (1) WO2012049307A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
TN2017000178A1 (en) * 2014-11-21 2018-10-19 Merck Sharp & Dohme Insulin receptor partial agonists
ES2908373T3 (es) 2015-08-25 2022-04-28 Novo Nordisk As Nuevos derivados de insulina y los usos médicos de los mismos
US20190010206A1 (en) * 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
CN108368163A (zh) * 2015-08-25 2018-08-03 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
CN109414408B (zh) * 2016-05-16 2022-03-29 得克萨斯州大学系统董事会 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
US10919949B2 (en) 2017-08-17 2021-02-16 Novo Nordisk A/S Acylated insulin analogues and uses thereof
KR20210102347A (ko) 2018-12-11 2021-08-19 사노피 인슐린 수용체 결합 친화성이 감소된 인슐린 유사체
JP7640462B2 (ja) * 2019-03-29 2025-03-05 ノヴォ ノルディスク アー/エス グルコース感受性インスリン誘導体
DK4073097T3 (da) 2019-12-11 2024-08-19 Novo Nordisk As Nye insulinanaloger og anvendelser heraf

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132404A3 (en) * 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
US20080171695A1 (en) * 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
US8097584B2 (en) 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
US9150633B2 (en) * 2007-08-15 2015-10-06 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
ES2561208T3 (es) * 2008-09-12 2016-02-25 Novo Nordisk A/S Método de acilación de un péptido o una proteína
EP2344200A2 (en) 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
EP2370059A1 (en) 2008-11-28 2011-10-05 Novo Nordisk A/S Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides
CA2786953A1 (en) 2010-01-12 2011-07-21 Florian Anders Foeger Pharmaceutical compositions for oral administration of insulin peptides

Similar Documents

Publication Publication Date Title
JP2013540771A5 (enExample)
WO2011153493A3 (en) Biodegradable lipids for the delivery of active agents
WO2008137758A3 (en) Amino acid lipids and uses thereof
MX2014014902A (es) Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
EP4286012A3 (en) Compounds and compositions for intracellular delivery of therapeutic agents
PE20171095A1 (es) Acidos grasos novedosos y su uso en la conjugacion con biomoleculas
EP2810661A3 (en) Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP4410317A3 (en) Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2011141705A8 (en) Novel cationic lipids and methods of use thereof
WO2010147655A3 (en) Compositions and methods relating to nucleic acid delivery vehicles
EP4614148A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
WO2014014613A3 (en) Self-assembling peptides, peptide nanostructures and uses thereof
EP4241767A3 (en) Novel lipids and compositions for the delivery of therapeutics
WO2015184256A3 (en) Biodegradable lipids for delivery of nucleic acids
WO2012054500A3 (en) Compositions for drug administration
WO2008052173A8 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2012069836A3 (en) Biologically active complex and its preparation
WO2015048498A3 (en) Carrier-free biologically-active protein nanostructures
EP4282412A3 (en) N-alkylaryl-5-oxyheteroaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b
EP3037417A3 (en) 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
Muthukumarasamyvel et al. Hierarchical self-assembly of bile-acid-derived dicationic amphiphiles and their toxicity assessment on microbial and mammalian systems
EP2928462A4 (en) METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID
RU2015140996A (ru) Топическая противомикробная дерматологическая композиция
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
HK1203157A1 (en) Sustained delivery of molecules using peptide surfactants and uses thereof